| Literature DB >> 35501080 |
Lijuan Wang1, Jiaojiao Ge1, Ying Chen1, Ying Liu1, Cong Li1, Yanan Dong1, Li Liu1,2, Yingqi Xing3,4.
Abstract
OBJECTIVE: To identify predictors of young Chinese patients with ischaemic stroke outcome and recurrence of stroke.Entities:
Keywords: stroke; stroke medicine
Mesh:
Year: 2022 PMID: 35501080 PMCID: PMC9062810 DOI: 10.1136/bmjopen-2021-052289
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Figure 1Flowchart of the study.
Figure 2TOASTand OCSP findings according to unfavourable outcomes and recurrence. (A) Comparison of TOAST classification between favourable and unfavourable outcomes. (B) Comparison of OCSP classification between favourable and unfavourable outcomes. (C) Comparison of TOAST classification between recurrence and non-recurrence. (D) Comparison of OCSP classification between recurrence and non-recurrence. CE, cardioembolism; LAA, large-artery atherosclerosis; LACS, lacunar syndrome; OCSP, Oxfordshire Community Stroke Project; PACS, partial anterior circulation syndrome; POCS, posterior circulation syndrome; SVD, small-vessel disease; TACS, total anterior circulation syndrome; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UDE, undetermined aetiology.
Figure 3mRS score at the 12-month follow-up. mRS, modified Rankin Scale.
Comparison of the characteristic data about favourable/unfavourable outcomes and recurrence/non-recurrence
| Demographic data and risk factors | N (%) | N (%) | ||||
| mRS | P value | Recurrence | P value | |||
| Favourable | Unfavourable | Yes | No | |||
| Sex, male (%) | 395 (80.9) | 74 (81.3) | 0.933 | 33 (71.7) | 436 (81.8) | 0.095 |
| Age (years), median (IQR) | 45.0 (40.0–47.0) | 45.0 (41.0–47.0) | 0.451 | 46.0 (43.0–47.0) | 45.0 (40.0–47.0) | 0.190 |
| Age ≥45 years (%) | 251 (51.4) | 52 (57.1) | 0.317 | 31 (67.4) | 272 (51.0) | 0.033 |
| BMI (kg/m2), median (IQR) | 24.80 (23.50–26.87) | 24.73 (23.44–27.77) | 0.886 | 24.68 (23.55–26.81) | 24.77 (23.44–27.06) | 0.608 |
| Rural, n (%) | 231 (47.3) | 45 (49.5) | 0.711 | 23 (50.0) | 253 (47.5) | 0.741 |
| Referred to the hospital | 131 (26.8) | 24 (26.4) | 0.926 | 146 (26.6) | 9 (30.0) | 0.104 |
| GCS score, median (IQR) | 15 (13–15) | 13 (13–15) | <0.001 | 15 (13–15) | 15 (13–15) | 0.400 |
| Baseline NIHSS score, median (IQR) | 3 (1–6) | 6 (3–10) | <0.001 | 4 (1–9) | 3 (1–6) | 0.272 |
| Hypertension | 278 (57.0) | 50 (54.9) | 0.721 | 25 (54.3) | 303 (56.8) | 0.743 |
| Hyperlipidaemia | 266 (54.5) | 51 (56.0) | 0.787 | 24 (52.2) | 293 (55.0) | 0.715 |
| Diabetes | 117 (24.0) | 29 (31.9) | 0.111 | 14 (30.4) | 132 (24.8) | 0.396 |
| Hyperhomocysteinaemia | 136 (27.9) | 21 (23.1) | 0.345 | 11 (23.9) | 146 (27.4) | 0.611 |
| CHD | 26 (5.3) | 4 (4.4) | 1.000 | 2 (4.3) | 28 (5.3) | 1.000 |
| AF | 7 (1.4) | 4 (4.4) | 0.078 | 5 (10.9) | 6 (1.1) | 0.001 |
| Cancer | 1 (0.2) | 2 (2.2) | 0.066 | 0 (0) | 3 (0.6) | 1.000 |
| Heart failure | 4 (0.8) | 1 (1.1) | 0.576 | 1 (2.2) | 4 (0.8) | 0.340 |
| VHD | 5 (1.0) | 1 (1.1) | 1.000 | 2 (4.3) | 4 (0.8) | 0.075 |
| Migraine | 18 (3.7) | 2 (2.2) | 0.754 | 2 (4.3) | 18 (3.4) | 0.668 |
| Alcohol | 255 (52.3) | 52 (57.1) | 0.391 | 22 (47.8) | 285 (53.5) | 0.462 |
| Smoke | 0.276 | 0.285 | ||||
| Never | 169 (34.6) | 29 (31.9) | 20 (43.5) | 178 (33.4) | ||
| Ex-smoker | 23 (4.7) | 8 (8.8) | 1 (2.2) | 30 (5.6) | ||
| Current smoker | 296 (60.7) | 54 (59.3) | 25 (54.3) | 325 (61.0) | ||
| Family history of stroke | 88 (18.0) | 17 (18.7) | 0.883 | 9 (19.6) | 96 (18.0) | 0.793 |
AF, atrial fibrillation; BMI, body mass index; CHD, coronary heart disease; GCS, Glasgow Coma Scale; NIHSS, National Institutes of Health Stroke Scale; VHD, valvular heart disease.
Comparison of the characteristic data about mRS with a score of 0–1, 2, 3–5 and 6
| Demographic data and risk factors | N (%) | P value | |||
| mRS | |||||
| 0–1 | 2 | 3–5 | 6 | ||
| Sex, male (%) | 395 (80.9) | 52 (85.2) | 16 (80.0) | 6 (60.0) | 0.303 |
| Age (years), median (IQR) | 45.0 (40.0–47.0) | 45.0 (41.5–47.0) | 46 (39.5–47.5) | 45 (43.0–47.0) | 0.867 |
| Age ≥45 years (%) | 251 (51.4) | 34 (55.7) | 11 (55.0) | 7 (70.0) | 0.317 |
| BMI (kg/m2), median (IQR) | 24.80 (23.50–26.87) | 24.815 (23.66–27.78) | 25.24 (23.55–25.14) | 22.67 (21.26–24.16) | 0.087 |
| Rural, n (%) | 231 (47.3) | 29 (47.5) | 11 (55.0) | 5 (50.0) | 0.935 |
| Referred to the hospital | 131 (26.8) | 15 (24.6) | 6 (30.0) | 3 (30.0) | 0.930 |
| GCS score, median (IQR) | 15 (13–15) | 13 (13–15) | 15 (12–15) | 13.5 (13–15) | 0.004 |
| Baseline NIHSS score, median (IQR) | 3 (1–6) | 6 (3–10) | 8 (3–12) | 3 (1–6) | <0.001 |
| Hypertension | 278 (57.0) | 30 (49.2) | 13 (65.0) | 7 (70.0) | 0.460 |
| Hyperlipidaemia | 266 (54.5) | 35 (57.4) | 12 (60.0) | 4 (40.0) | 0.725 |
| Diabetes | 117 (24.0) | 19 (31.1) | 5 (25.0) | 5 (50.0) | 0.176 |
| Hyperhomocysteinaemia | 136 (27.9) | 14 (23.0) | 4 (20.0) | 3 (30.0) | 0.791 |
| CHD | 26 (5.3) | 2 (3.3) | 1 (5.0) | 1 (10.0) | 0.676 |
| AF | 7 (1.4) | 1 (1.6) | 1 (5.0) | 2 (20.0) | 0.011 |
| Cancer | 1 (0.2) | 0 (0) | 1 (5.0) | 1 (10.0) | 0.010 |
| Heart failure | 4 (0.8) | 0 (0) | 0 (0) | 1 (10.0) | 0.109 |
| VHD | 5 (1.0) | 0 (0) | 0 (0) | 1 (10.0) | 0.143 |
| Migraine | 18 (3.7) | 2 (3.3) | 0 (0) | 0 (0) | 1.000 |
| Alcohol | 255 (52.3) | 38 (62.3) | 10 (50.0) | 4 (40.0) | 0.391 |
| Smoke | 0.397 | ||||
| Never | 169 (34.6) | 20 (32.8) | 7 (35.0) | 2 (20.0) | |
| Ex-smoker | 23 (4.7) | 5 (8.2) | 1 (5.0) | 2 (20.0) | |
| Current smoker | 296 (60.7) | 36 (59.0) | 12 (60.0) | 6 (60.0) | |
| Family history of stroke | 88 (18.0) | 11 (18.0) | 3 (15.0) | 3 (30.0) | 0.752 |
AF, atrial fibrillation; BMI, body mass index; CHD, coronary heart disease; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; VHD, valvular heart disease.
Distribution of ischaemic infarctions according to favourable/unfavourable outcomes and recurrence/non-recurrence
| Distribution of ischaemic infarctions | mRS | P value | Recurrence | P value | ||
| Favourable | Unfavourable | 0.145 | Yes | No | 0.624 | |
| Without new cerebral infarction | 25 (5.1) | 3 (3.3) | 3 (6.5) | 25 (4.7) | ||
| Multiple brain infarctions | 229 (46.9) | 55 (60.4) | 27 (58.7) | 257 (48.2) | ||
| 8 (1.6) | 0 (0) | 0 (0) | 8 (1.5) | |||
| 6 (1.2) | 0 (0) | 0 (0) | 6 (1.1) | |||
| 3 (0.6) | 0 (0) | 0 (0) | 3 (0.6) | |||
| 2 (0.4) | 1 (1.1) | 0 (0) | 3 (0.6) | |||
| 13 (2.7) | 5 (5.5) | 3 (6.5) | 15 (2.8) | |||
| 47 (9.6) | 8 (8.8) | 2 (4.3) | 53 (9.9) | |||
| 41 (8.4) | 10 (11.0) | 2 (4.3) | 49 (9.2) | |||
| 38 (7.8) | 2 (2.2) | 1 (2.2) | 39 (7.3) | |||
| 51 (10.5) | 4 (4.4) | 6 (13.0) | 49(92) | |||
| 22 (4.5) | 3 (3.3) | 2 (4.3) | 23 (4.3) | |||
| 3 (0.6) | 0 (0) | 0 (0) | 3 (0.6) | |||
mRS, modified Rankin Scale.
Figure 4Distribution of artery stenosis according to unfavourable outcomes and recurrence. (A) Distribution of artery stenosis with favourable outcomes and unfavourable outcomes. (B) Distribution of artery stenosis with recurrence and non-recurrence. ACA, anterior cerebral artery; BA, basilar artery; CCA, common carotid artery; ICA, internal carotid artery; MAS, multiple artery stenosis; MCA, middle cerebral artery; PCA, posterior cerebral artery; SUBA, subclavian artery; VA, vertebral artery.
Comparison of different vascular imaging features
| mRS | Recurrence | |||||
| Favourable | Unfavourable | P value | Yes | No | P value | |
| Plaques | 311 (63.7) | 53 (58.2) | 0.320 | 28 (60.9) | 336 (63.0) | 0.770 |
| Stenosis | 240 (49.2) | 55 (60.4) | 0.049 | 29 (63.0) | 266 (49.9) | 0.087 |
| Distribution of stenosis | ||||||
| Intracranial/extracranial | 0.185 | 0.310 | ||||
| Normal | 248 (50.8) | 36 (39.6) | 17 (37.0) | 267 (50.1) | ||
| Intracranial | 180 (36.9) | 40 (44.0) | 22 (47.8) | 198 (37.1) | ||
| Extracranial | 35 (7.2) | 7 (7.7) | 3 (6.5) | 39 (7.3) | ||
| Both | 25 (5.1) | 8 (8.8) | 4 (8.7) | 29 (5.4) | ||
| Anterior/posterior | 0.264 | 0.398 | ||||
| Normal | 248 (50.8) | 36 (39.6) | 17 (37.0) | 267 (50.1) | ||
| Anterior | 153 (31.4) | 36 (39.6) | 19 (41.3) | 170 (31.9) | ||
| Posterior | 70 (14.3) | 15 (16.5) | 8 (17.4) | 77 (14.4) | ||
| Both | 17 (3.5) | 4 (4.4) | 2 (4.3) | 19 (3.6) | ||
| Degree of stenosis | 0.002 | 0.107 | ||||
| Normal or mild | 262 (53.7) | 38 (41.8) | 17 (37.0) | 283 (53.1) | ||
| Moderate | 34 (7.0) | 1 (1.1) | 4 (8.7) | 31 (5.8) | ||
| Severe or occlusion | 192 (39.3) | 52 (57.1) | 25 (54.3) | 219 (41.1) | ||
mRS, modified Rankin Scale.
Therapy during poststroke
| Treatments | mRS | P value | Recurrence | P value | ||
| Therapy during poststroke | Favourable | Unfavourable | Yes | No | ||
| Antiplatelet | 345 (70.7) | 62 (68.1) | 0.623 | 35 (76.1) | 372 (69.8) | 0.370 |
| Antihypertensive | 193 (69.4) | 30 (60.0) | 0.188 | 15 (60.0) | 208 (68.6) | 0.373 |
| Hypoglycaemic agents | 37 (31.6) | 9 (31.0) | 0.951 | 6 (42.9) | 40 (30.3) | 0.336 |
| Lipid lowering | 122 (45.9) | 25 (49.0) | 0.679 | 11 (45.8) | 136 (46.4) | 0.956 |
| Traditional Chinese medicine | 107 (21.9) | 24 (26.4) | 0.352 | 6 (13.0) | 125 (23.5) | 0.105 |
| Homocysteine-lowering therapy | 84 (61.8) | 7 (33.3) | 0.014 | 5 (45.5) | 86 (58.9) | 0.384 |
mRS, modified Rankin Scale.